Free Trial

Alnylam Pharmaceuticals (ALNY) Stock Forecast & Price Target

$236.70
-3.32 (-1.38%)
(As of 07/18/2024 ET)

Alnylam Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Based on 24 Wall Street analysts who have issued ratings for Alnylam Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 24 analysts, 8 have given a hold rating, and 16 have given a buy rating for ALNY.

Consensus Price Target

$253.55
7.12% Upside
High Forecast$400.00
Average Forecast$253.55
Low Forecast$150.00

According to the 24 analysts' twelve-month price targets for Alnylam Pharmaceuticals, the average price target is $253.55. The highest price target for ALNY is $400.00, while the lowest price target for ALNY is $150.00. The average price target represents a forecasted upside of 7.12% from the current price of $236.70.

TypeCurrent Forecast
7/20/23 to 7/19/24
1 Month Ago
6/20/23 to 6/19/24
3 Months Ago
4/21/23 to 4/20/24
1 Year Ago
7/20/22 to 7/20/23
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
16 Buy rating(s)
10 Buy rating(s)
10 Buy rating(s)
14 Buy rating(s)
Hold
8 Hold rating(s)
7 Hold rating(s)
8 Hold rating(s)
4 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$253.55$216.19$216.12$251.00
Forecasted Upside7.12% Upside34.66% Upside32.88% Upside23.82% Upside
Get Alnylam Pharmaceuticals Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for ALNY and its competitors with MarketBeat's FREE daily newsletter.

ALNY Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ALNY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Alnylam Pharmaceuticals Stock vs. The Competition

TypeAlnylam PharmaceuticalsMedical CompaniesS&P 500
Consensus Rating Score
2.67
2.71
2.50
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside7.24% Upside1,413.75% Upside8.20% Upside
News Sentiment RatingPositive News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
7/12/2024Morgan Stanley
3 of 5 stars
 Boost TargetEqual Weight ➝ Equal Weight$250.00 ➝ $255.00-3.04%
7/8/2024Canaccord Genuity Group
1 of 5 stars
 Boost TargetBuy ➝ Buy$283.00 ➝ $357.00+40.09%
7/3/2024JPMorgan Chase & Co.
3 of 5 stars
 Boost TargetNeutral ➝ Neutral$160.00 ➝ $248.00+0.40%
7/1/2024Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingNeutral ➝ Neutral$150.00 ➝ $150.00-38.27%
6/28/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
E. Merle
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy ➝ Buy$253.00 ➝ $288.00+18.37%
6/27/2024Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$215.00 ➝ $295.00+20.32%
6/25/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$227.00 ➝ $291.00+21.20%
6/25/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$248.00 ➝ $295.00+24.08%
6/25/2024TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$260.00 ➝ $282.00+18.57%
6/25/2024SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetMarket Perform ➝ Market Perform$138.00 ➝ $159.00-33.15%
6/25/2024Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$235.00 ➝ $250.00+8.08%
6/25/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$236.00 ➝ $291.00+25.81%
6/25/2024Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
L. Bayko
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOutperform ➝ Outperform$210.00 ➝ $260.00+12.40%
6/25/2024Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetEqual Weight ➝ Equal Weight$161.00 ➝ $207.00-9.85%
6/24/2024Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$200.00 ➝ $275.00+21.00%
6/24/2024BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform ➝ Outperform$234.00 ➝ $234.00+3.28%
6/24/2024HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$400.00 ➝ $400.00+76.55%
5/3/2024Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$225.00 ➝ $225.00+49.69%
4/8/2024William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform
2/16/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Neutral$230.00 ➝ $173.00+17.34%
2/15/2024Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoveragePeer Perform
12/14/2023Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$210.00 ➝ $217.00+15.12%
10/11/2023Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Market Perform
10/10/2023Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$237.00 ➝ $218.00+28.97%
9/28/2023Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$208.00+19.52%
4/26/2023Sumitomo Mitsui Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageNeutral$220.00+8.83%
2/21/2023EF Hutton Acquisition Co. I
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$304.00+48.68%
10/3/2022Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$218.00 ➝ $232.00+15.91%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 01:25 AM ET.

ALNY Forecast - Frequently Asked Questions

What is Alnylam Pharmaceuticals' forecast for 2024?

According to the research reports of 24 Wall Street equities research analysts, the average twelve-month stock price forecast for Alnylam Pharmaceuticals is $253.55, with a high forecast of $400.00 and a low forecast of $150.00.

Should I buy or sell Alnylam Pharmaceuticals stock right now?

24 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Alnylam Pharmaceuticals in the last year. There are currently 8 hold ratings and 16 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ALNY shares.

Does Alnylam Pharmaceuticals's stock price have much upside?

According to analysts, Alnylam Pharmaceuticals's stock has a predicted upside of 13.60% based on their 12-month stock forecasts.

Do Wall Street analysts like Alnylam Pharmaceuticals more than its competitors?

Analysts like Alnylam Pharmaceuticals less than other "medical" companies. The consensus rating score for Alnylam Pharmaceuticals is 2.67 while the average consensus rating score for "medical" companies is 2.72. Learn more on how ALNY compares to other companies.


This page (NASDAQ:ALNY) was last updated on 7/19/2024 by MarketBeat.com Staff

From Our Partners